Clinical trials: Glucagon
Healthy
Physical Training and the Incretin Effect
It is well known that continuous physical exercise leads to a number of changes in the body. Maximal oxygen uptake; the heart's pumping ability and muscle mass and strength increases.
- Trial name
- EXINT2 (NCT01698502)
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Type 2 Diabetes Mellitus
The Effects of Bethanechol on Glucose Homeostasis
Xenin-25 and glucose-dependent insulinotropic polypeptide (GIP) are hormones produced in the intestine that are released into the blood immediately after ingestion of a meal.
- Trial name
- NCT01434901
- Testing
- Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Autosomal Dominant Polycystic Kidney, Obesity
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can…
- Trial name
- NCT06582875
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Colorado, Denver
Pancreatectomy; Hyperglycemia
Separate and Combined Extrapancreatic Effects of the Incretin Hormones
The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas.
- Trial name
- GA-19 (NCT05177653)
- Testing
- Intravenous infusion
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Polycystic Ovary Syndrome
Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
The purpose of this study was to determine whether metformin combined with exenatide once weekly (EQW) is more effective than metformin alone in the treatment of overweight/obese women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT04029272
- Testing
- Metformin, Exenatide 2 MG
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Overweight and/or Obesity, Weight Management
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
- Trial name
- NCT07243171
- Testing
- ecnoglutide tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Diabetes Mellitus, Type 1
Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM
We aim to demonstrate that oral administration of glibenclamide stimulates pancreatic glucagon secretion during hypoglycemia in insulin-deficient (C-peptide negative) patients with type 1 diabetes when compared to type 1 diabetic…
- Trial name
- NCT00515801
- Testing
- glibenclamide
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Basel, Switzerland
Type 1 Diabetes, Hypoglycemia
Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
The primary aim of the study is to compare the efficacy of single-administration low-dose glucagon and split-administration low-dose glucagon to placebo for prevention of exercise-induced hypoglycemia in people with type 1…
- Trial name
- NCT05076292
- Testing
- GlucaGen, Saline
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Surgical Treatment of Non-obese Type 2 Diabetic Patients With Duodenal Exclusion
Diabetes reversion is observed after bariatric surgeries even before significant weight loss could explain it, mainly in predominantly malabsorptive procedures (98,9% for biliopancreatic diversion or duodenal switch), followed by…
- Trial name
- NCT00566358
- Testing
- Duodenal exclusion surgery
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- University of Campinas, Brazil
Healthy Participants
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
The purpose of this study is to assess the pharmacokinetics (PK), safety and tolerability of different oral formulations of AZD5004, and to evaluate the effect of food on these formulations in healthy participants.
- Trial name
- NCT07455825
- Testing
- AZD5004
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pancreatectomy; Hyperglycemia
Separate and Combined Extrapancreatic Effects of GIP and GLP-1
The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas.
- Trial name
- GA-19b (NCT06895408)
- Testing
- Intravenous Infusion
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity, Weight Management
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
- Trial name
- NCT07073417
- Testing
- XW003 injection, semaglutide injection
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Hypoparathyroidism
Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.
Hypoparathyroidism (hypoPT) is characterized by low levels of PTH. In this study we will test the effects of a liquid meal on the bone remodeling in participants with hypoparathyroidism.
- Trial name
- KS-4-HypoPT (NCT03728959)
- Testing
- Liquid meal (Nutridrink), GIP, GLP-2
- Where
- Denmark
- Volunteers
- 7 people
- Sponsor
- University of Copenhagen
Type 1 Diabetes
Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).
- Trial name
- NCT02018627
- Testing
- Xeris glucagon, Lilly glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Steven J. Russell, MD, PhD
Type-2 Diabetes, Healthy
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
The purpose of this study is to assess the GLP-1 and non-GLP-1 effects of LAF237 on glucagon secretion, using treatment observations of the overall glycemic response.
- Trial name
- NCT00651105
- Testing
- Vildagliptin
- Where
- 2 sites in Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
The drug effects will be studied after a single dose of 50 milligram (mg) albiglutide and a single dose of 10 microgram exenatide, to gain insight into the central mechanisms of nausea associated with Glucagon-like peptide-1…
- Trial name
- NCT02802514
- Testing
- Albiglutide 50mg, Exenatide 10microgram
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
This study will compare hemoglobin a1c (HbA1c) and cardiovascular (CV) outcomes among patients with type 2 diabetes newly initiating a GLP1-receptor agonist or basal insulin.
- Trial name
- NCT04034524
- Testing
- GLP-1 receptor agonist, Insulin
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Brigham and Women's Hospital